10 August 2020 - The Scottish Medicines Consortium has today published advice accepting neratinib (Nerlynx) for the treatment of breast cancer.

Neratinib is used to treat patients with early hormone receptor positive HER2 positive breast cancer who have had surgery. 

This decision was expedited as part of an approach to minimise delay in issuing SMC advice following the suspension of meetings during the early phase of the COVID-19 pandemic.

SMC is now in the process of resuming meetings.

Read SMC press release